Pharmaceutical Companies Archives - Page 2 of 2

StayHappi Pharmacy – Making HealthCare Affordable with Generic Medicines!

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by the organization it is StayHappi.

Medicine is considered to be one of the most important necessities for all of us. It is concerned with maintaining and restoring human health, and the role of a pharmacist is vital for the benefit of the patients. With the rapid growth of the pharmaceutical industry, the market players need to provide these lifesaving drugs at a fair financial value that is of the best quality as well.

A humanitarian belief is that everyone should be able to get the opportunity and access to necessities that include medicine and health-care as well. To provide these life-saving high-quality medicines, drugs, and prescription remedies at an affordable price is what StayHappi envision. StayHappi Pharmacy practices this right and serves these legitimate medicines at the right costs by providing them the authority to make this right choice. They offer High-Quality Generic medicines at 30- 90% lower MRP than the branded medicines and progressing towards making Healthcare more affordable.

Read more about StayHappi Company Profile, Founders, Business Model, Revenue, Growth, Pharma Industry etc.,

StayHappi Pharmacy- Company Highlights

Startup Name	StayHappi
Headquarter	Delhi, India
Sector	Pharmacy
Founders	Ms. Arushi Jain
Founded	October 2017
Parent Organization	SarvaGunAushdhi Private Limited
Website	stayhappi.in

StayHappi – About and How it Works
StayHappi – Pharmacy Industry
StayHappi – Founders and Team
StayHappi – Name, Tagline, and Logo
StayHappi – Product and Services
StayHappi – Business Model and Revenue Model
StayHappi – User Acquisition and Growth
StayHappi – Startup Challenges
StayHappi – Make In India Initiative
StayHappi – Future Plans
StayHappi – FAQs

StayHappi – About and How it Works

StayHappi Pharmacy was incepted with a firm belief to serve humanity by providing High-Quality Generic Medicines at ‘Real and Affordable’ prices. It provides medicines with their molecule name and not by the brand name, where patients will have the power to choose the right medicine and make a smart choice.

Generic medicines are as good as branded medicines and have similar dosage, intended use, effects, and side effects, route of administration, risks, safety, and strength as the original drug. Their low prices offer High Value to the patients as the company aim to provide quality healthcare at affordable prices for everyone and everywhere.

StayHappi Pharmacy partners with retail outlets/sub-franchisee, manufacturers, and development partners for increased access to medicines for everyone. Their partners manufacture about 15% of the country’s total medicinal consumption and maintain the highest standards of quality. Their facilities are regularly audited and approved for manufacturing by regulating authorities like the US FDA, WHO GMP, USNSF, NABL, PICS, ISO 9001-2008, and ISO 14001-2015.

The company has a central warehouse and a robust supply chain with a distribution network across all states in the country. Thus it creates employment opportunities for thousands of pharmacists, doctors, and business opportunities for entrepreneurs.

StayHappi pharmacy is progressing towards the expansion of Retail Pharmacy Stores along with online Presence across India to make Healthcare more affordable.

StayHappi – Pharmacy Industry

The pharmacy market in India is primarily governed by the branded drugs in terms of the methodology of how Indians buy their Medicines. But, now the trend is changing into a generic base but it is going to take a long time before it gets into the culture of the Indian population from the generic perspective.

StayHappi – Founders and Team

StayHappi was founded by Arushi Jain who leads the company as an executive director.

Arushi Jain - Owner of StayHappi Pharmacy — Arushi Jain – Founder, StayHappi Pharmacy

Dr. Sujit Paul is Managing Director of StayHappi. He is a proven leader and part of Top Management with board-level experience, Dr. Sujit Paul, aged 42, has extensive exposure to multi-national as well as large and medium-sized organizations in various corporate culture and carries over 20 years of experience. He also received an award as a World’s Greatest Leader 2018-2019 Asia & GCC in Dubai.

Other than a thriving professional life, Sujit enjoys reading and travelling across the globe and works for stray animals. He is a believer in ground-level realities and possesses a strong team-building attitude.

StayHappi team has over 30 years of experience in the pharmaceutical industry from manufacturing, supply chain, distribution, and marketing. Since its inception, the company has hired experienced and erudite executives from pharmaceutical and retail industries who work towards ensuring that the company achieves what it aims towards the end consumers and patients.

StayHappi – Name, Tagline, and Logo

The mission of the startup is to ensure that everyone stays more healthy and happy, so ‘StayHappi’ and the logo depict the ‘happy human’. And hence, it has a connotation with the word StayHappi and a logo as what it is.

StayHappi Pharmacy Logo

StayHappi – Product and Services

The company deals with products like Allopathic, Ayurvedic, Herbal medicines, Neutraceuticals, OTC, Consumables, Cosmetics, Surgical items and Medical Devices.

StayHappi pharmacy provides high quality generic medicine, so that people get the best allopathic medicines at the least price possible. They offer a complete range of high quality allopathic medicines across all major therapeutic segments at affordable prices. The demand for Nutraceuticals is on a surge and StayHappi provides these products as well.

StayHappi Stores provide Ayurvedic Medicines as well, to complete the basket of healthcare and cater to people who have an affinity towards Ayurvedic and Herbal Medicines. Their Ayurvedic Product Range covers the following segments: Respiratory, Cough and Cold, Rejuvenating Agent, Liver Support, Memory Support, Anti-inflammatory, Arthritis Support, Laxative, Skin Health, Tonics, Digestive Aid, Circulation Support, Blood Sugar Support, etc.

Apart from this, medical consumables and cosmetics are also available at StayHappi Stores. It is the one-stop shop for customers’ healthcare and wellness needs. The wide range of products caters to all kinds of customers’ needs. It offers a variety of quality-certified and low-priced generic alternatives to all your essential healthcare and grooming products. So now, you can start saving a considerable amount on your monthly expenses.

StayHappi offers a range of quality-certified healthcare equipment that you can rely on. What’s more, they also help reduce your critical care bills substantially.

StayHappi – Business Model and Revenue Model

StayHappi Pharmacy is broadening its horizon to reach the customers via all the platforms. Thus, it is a combination of an offline and online segment, covering the wide market. Being available at all the platforms helps the brand to understand the pattern and how to mold its strategies to cater to the patients/customers. Its business model follows ethical trading medium with major onset on retail outlets. It also follow franchise and store-in-store model where a kiosk is set up in an existing outlet introducing customers to the medicines. By ordering medicines in bulk, the overall cost of the product is low. With StayHappi Pharmacy, customers can purchase high-quality generic medicines at prices that are 30%-90% less than the commonly retailed price of the same medicine in India.

The brand’s revenue model is definitely there, in terms of getting more and more retail stores and thereby when the medicines are handed over to the end consumers definitely revenue rotates on its own perspective. The similar revenue model also rotates when from the online platform a medicine reaches the household.

StayHappi – User Acquisition and Growth

At every business level, the flexibility is scaled up through mantra and one who is flexible and reliable along with a thorough understanding of the market can lead to success. StayHappi Pharmacy is doing lots of marketing campaigns all across offline, online, ATL, and BTL to make consumers more aware of buying high-quality medicines at affordable prices and that’s how it happens.

“Getting the first customer was a little painful because Indians primarily believes in buying branded drugs or drugs that the clinicians have written in the prescription. So, it was a fight and the brand slowly started winning from 1 to 2 and 2 to 4 and 4 to thousands of users”, says Arushi Jain, StayHappi founder.

People started believing that yes, StayHappi actually offers good high-quality medicines. So, it is the brand’s continuous endeavor to plant-in the ideals to the end consumers by saying that you have an option to actually and effectively save money in your bills which you can do by buying a good quality branded generic. This methodology is still working.

The brand opened its first store in May 2018 and in just one year, the brand has been able to open its stores 279 locations across 67 cities in 12 states including Delhi/NCR, Punjab, Uttar Pradesh, Bihar, Karnataka, Kerala, Tamil Nadu, Noida, Tiruchirappalli, Mumbai, Bhakal, Kolkata, Puducherry, Erode & Chennai, and more.

StayHappi – Startup Challenges

The challenge that StayHappi faced initially was clinicians writing branded drugs in the prescription. For many years, consumers and patients are under the impression that they will consume only what the clinicians write. So, to overcome that, the startup started to educate the common mass and once they understand the true value of it, then they are sticking to it. A few of the methods were advertisement in newspapers, radio along with organizing health camps.

The company also faces tough challenges especially in partnering with retailers. right from pitching, to convincing, to getting up the signage, and eventually ensuring product availability is really a tough challenge but the company has been successful in overcoming it.

StayHappi – Make In India Initiative

In consonance with the Prime Minister’s vision, StayHappi is a nationwide chain of retail pharmacies to support ‘Make in India‘ drive with quality medicines and other healthcare products at realistic prices.

The current universe is dominated by brands where marketing companies expend exorbitant amounts of resources to drive demand of particular brands, and patients get these medicines at very high prices. StayHappi pharmacy will fulfill the government’s aspiration to implement the Uniform Code of Pharmaceuticals Marketing Practices (UCPMP) without any efforts or legislative compulsion with respect to availability of high quality medicines.

StayHappi – Future Plans

StayHappi plans to scale up and reach every nook and corner in the country and to make “Health for all” a reality. A combination of an offline and online platform at an affordable medicine segment with high quality will definitely be a beneficial combination to move ahead. So, the future plan of the brand is to build a robust mechanism of an online platform clubbed with an offline.

It plans to add 1,000 retail pharmacy stores by 2020 and will launch 1,000 products in a phased manner. Subsequently, the company will increase the product mix that would offer a comprehensive range of products covering all types of therapeutic form, dosage forms, consumables, and healthcare products.

StayHappi – FAQs

Who is the Founder of StayHappi?

StayHappi was founded by Arushi Jain who leads the company as an executive director.

What is StayHappi Phramacy Revenue?

StayHappi generates around $4.6M in revenue

What does StayHappi Pharmacy offer?

It provides High-Quality Generic Medicines at ‘Real and Affordable’ prices

What is Generic Medicine?

Generic drugs are copies of brand-name drugs that have exactly the same dosage, intended use, effects, side effects, route of administration, risks, safety, and strength as the original drug

Is Generic Medicine safe to use?

Yes. Generic Drugs are regulated and go through a review process before they’re approved. The FDA tests them to make sure they offer the same benefits as brand-name medications and that any different ingredients used in the generic drug are safe.

August 9, 2021

Pfizer – One of the Leading Biopharmaceutical Companies In the World

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Pfizer.

Health and Human Services Secretary Alex Azar said that the US was currently manufacturing doses for all six potential vaccines backed by President Donald Trump’s government across more than 23 manufacturing facilities. These includes vaccines from Moderna, Pfizer, AstraZeneca and Johnson & Johnson, which are all in late-stage testing.

Pfizer is a research-based multinational biopharmaceutical corporation that develops, manufactures, and distributes healthcare products. Medicines and vaccines are part of its global portfolio. The Pfizer–BioNTech COVID-19 vaccine is an mRNA-based COVID-19 vaccine that is marketed under the brand name Comirnaty. It is given to people aged 16 and up to protect them from infection with the SARS-CoV-2 virus, which causes COVID-19.

This article will give you a complete Company Profile of Pfizer. Know all about Pfizer history, business model, founders, revenue, acquisition, covid-19 vaccine & more…

Pfizer – Company Highlights

Company Name	Pfizer Inc.
Headquarters	New York City, New York
Industry	Pharmaceutical
Founders	Charles Pfizer and Charles F. Erhart
Founded	1849
Products	Pharmaceuticals, vaccines
Current CEO	Albert Bourla
Areas Served	Worldwide
Website	pfizer.in

Pfizer – Latest News
About Pfizer and How it Works?
Pfizer – Mission and Vision
Pfizer – Founder and History
Pfizer – Covid-19 Vaccine
Pfizer – Key Pharmaceutical Products
Pfizer – Name, Logo, and Tagline
Pfizer – Business Model
Pfizer – Key Financial Metrics
Pfizer – Revenue and Growth
Pfizer – Investments
Pfizer – Acquisitions
Pfizer – Competitors
Pfizer – Challenges Faced
Pfizer – Future Plans
Pfizer – FAQs

Pfizer – Latest News

Pfizer/BioNTech has filed an application with the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people aged 16 and up as of May 2021, according to the companies. This is the first Covid-19 vaccine to be evaluated by the FDA for complete approval in the United States.

The FDA has granted emergency use authorization (EUA) to Pfizer’s mRNA two-shot vaccine for use in the United States. To date, 170 million doses of the vaccine have been distributed throughout the United States, according to the firms.

“We are proud of the tremendous progress we’ve made since December in delivering vaccines to millions of Americans, in collaboration with the U.S. Government,” Albert Bourla CEO of Pfizer, said in a statement.

“We look forward to working with the FDA to complete this rolling submission and support their review, with the goal of securing full regulatory approval of the vaccine in the coming months.”

About Pfizer and How it Works?

Pfizer is a research-based multinational biopharmaceutical corporation that develops, manufactures, and distributes healthcare products. Medicines and vaccines are part of its global portfolio.

Cholesterol-lowering Lipitor, pain-relieving Celebrex and Lyrica, pneumonia vaccine Prevnar, and erectile dysfunction medication Viagra, as well as arthritis medicine Enbrel, antibiotic Zyvox, and blood-thinning Eliquis, are among the company’s top prescription items. Generic medications and consumer health goods are also manufactured and sold by the company.

In partnership with BioNTech SE, a German biotechnology firm, Pfizer recently produced an mRNA-based vaccine for COVID-19. The vaccine’s efficacy has been verified in several trials to be between 90 and 100 percent.

Pfizer – Mission and Vision

The vision statement of Pfizer is – “Innovate to bring therapies to patients that significantly improve their lives.”

Pfizer mission statement is “to become the world’s most valued company to all of these people.” It zeroes down on the achievements that the company desires while at the same time meeting the expectations of all its patients. It focuses on the company’s desired outcomes while still meeting all of its patients’ needs.

Pfizer – Founder and History

Charles Pfizer and Charles Erhart, cousins who had immigrated to the United States from Ludwigsburg, Germany, founded Pfizer in 1849.

The company, which was based on Bartlett Street in Williamsburg, New York, developed chemical compounds, including an antiparasitic called santonin. Both in their mid-20s, the two men started a fine chemicals company in a Brooklyn factory with a loan from Pfizer’s father. Pfizer’s chemist skills were combined with Erhart’s confectioner training in the company’s first product, a palatable anti-parasitic drug that tasted like toffee. It was a huge success, and it set the tone for the company’s future growth.

The American Civil War, which broke out shortly after in 1862, had an equal effect on the emerging pharmaceutical industry as it did on American society as a whole. Drug manufacturers were just as much a part of the “first industrial war” as arms manufacturers. The sudden demand for massive amounts of painkillers and antiseptics for the Union armies, like that of their rival Squibb, presented a huge opportunity to increase production. Pfizer’s sales had doubled since the beginning of the war in 1868, and their product ranges had greatly expanded.

Following the battle, Pfizer began to concentrate on industrial chemicals rather than drugs, manufacturing citric acid for the burgeoning soft drink industry, which fueled the expansion of brands including Coca-Cola and Dr. Pepper in the 1880s. For several years, this was their mainstay, setting the groundwork for their continued expansion. When the supply of tartaric acid was interrupted by the civil war and higher tariffs, Pfizer expanded its production to become the leading chemical supplier in the United States.

Pfizer – Covid-19 Vaccine

In April 2020, Pfizer collaborated with BioNTech to start developing a COVID-19 vaccine in response to the coronavirus pandemic. The BNT162b2 vaccine candidate is an mRNA vaccine. The drug-maker announced in November 2020 that results from Phase 3 clinical trials showed the vaccine was safe and reliable, with a 95 percent efficacy rate. It needs two doses, separated by 21 days.

Pfizer and BioNTech submitted an emergency use permission request to the FDA a few days after the positive clinical trial results were announced. The FDA approved the Pfizer-BioNTech COVID-19 vaccine for distribution in the United States on December 11, 2020.

Pfizer – Key Pharmaceutical Products

Many well-known products are manufactured and marketed by Pfizer. Some of the company’s most well-known brands are mentioned below –

Nexium24HR – Over-the-counter heartburn drug
Prevnar 13 – Vaccine to prevent pneumonia
Advil – Non-steroidal anti-inflammatory drug (pain reliever)
Viagra – Erectile dysfunction drug
Xanax – Psychoactive medicine
Zoloft – SSRI antidepressant
Lipitor – Cholesterol medicine
Chantix – Smoking cessation drug
Bextra – Cox-2 inhibitor (pain reliever)
Depo-Testosterone – Testosterone replacement therapy drug
EpiPen – Auto-injector emergency allergy medicine
Celebrex – Non-steroidal anti-inflammatory drug (pain reliever)
Zithromax – Macrolide antibiotic (bacterial infections)
Eliquis – Anticoagulant (blood thinner)
Protonix – Proton pump inhibitor acid-reducer
Prempro – Hormone replacement drug therapy
Effexor – SNRI antidepressant

Pfizer – Name, Logo, and Tagline

Pfizer’s company name is after the founder Charles Pfizer and its logo is shaped like a tablet of medicine. The oval-shaped logo is a powerful brand identity that conveys a message of optimism, well-being, and progress. As opposed to the initial limit “P,” the letter “f” is intentionally made larger.

The tagline outlines Pfizer’s purpose, “Breakthroughs that change patients’ lives.”

Pfizer’s Company Logo

Pfizer – Business Model

Pfizer Innovative Health and Pfizer Essential Health are the company’s two commercial divisions.

Pfizer Innovative Health is dedicated to the development and commercialization of pharmaceuticals and vaccines. Internal medicine, vaccination, oncology, inflammation and immunology, rare diseases, and consumer healthcare are among IH’s therapeutic fields.

Legacy labels, branded generics, generic sterile injectable drugs, biosimilars, and infusion systems are all included in the Pfizer Essential Health category. EH also has a research and development department, as well as a contract manufacturing division. Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq, and Viagra are some of the company’s brands.

Pfizer – Key Financial Metrics

The table below highlights some of the key financial metrics of Pfizer (extracted from the company’s annual reports)

Financial Metric	2020 (In Millions)	2019 (In Millions)
Total Income	$9,616	$16,273
PAT(Margin)	-11.89	219.75
Equity Share Capital	45.75	45.75
Net Fixed Assets	2513.05	2127.65

Pfizer – Revenue and Growth

Pfizer’s COVID-19 vaccine sales exceeded analyst expectations by about 60%. As of mid-April 2021, the company produced 1.6 billion doses of the vaccine under signed contracts. Pfizer’s operating sales increased by 8% even without revenue from the COVID-19 vaccine.

Year	Amount	Percentage Change From Last Year
2021	$14.582B	+21.23%
2020	$41.908B	+1.79%
2019	$41.172B	+0.85%
2018	$40.825B	-22.31%

Pfizer – Investments

Date	Organization Name	Round	Amount
Mar 30, 2021	Pyxis Oncology	Series B	$152M
Feb 17, 2021	Imcyse	Series B	€21.3M
Oct 29, 2020	LianBio	Venture Round	$310M
Jul 29, 2020	Cerevel Therapeutics	Post-IPO Equity	$320M
May 19, 2020	Amplyx Pharmaceuticals	Series C	$53M
Apr 22, 2020	FoRx Therapeutics	Seed Round	€10M
Mar 20, 2019	Vivet Therapeutics	Corporate Round	€45M
Feb 19, 2019	Gliknik	Corporate Round	$15M
Nov 13, 2018	NextCure	Series B	$93M
Apr 19, 2018	Allogene Therapeutics	Series A	$411.8M

Pfizer – Acquisitions

Acquiree Name	About Acquiree	Date	Amount
Amplyx Pharmaceuticals	Amplyx focuses on developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems	Apr 28, 2021	–
Array BioPharma	Array BioPharma is a biopharmaceutical company focused on the development and commercialization of targeted small molecule drugs.	Jun 17, 2019	$11.4B
Therachon	Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases	May 8, 2019	$340M
Medivation	Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases	Aug 22, 2016	$14B
Bamboo Therapeutics	Bamboo Therapeutics Announces the Acquisition of the Vector Core Manufacturing Facility from UNC-Chapel Hill	Aug 1, 2016	$654M
BIND Therapeutics	BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.	Jul 27, 2016	$40M
Anacor Pharmaceutical	Anacor Pharmaceutical is a biopharmaceutical company developing small-molecule therapeutics from its boron chemistry platform.	May 16, 2016	$5.2B
Hospira	Hospira is a provider of injectable drugs and infusion technologies.	Feb 5, 2015	$15B
Redvax	A privately held Swiss biopharmaceutical company	Jan 5, 2015	–
Baxter International – Marketed Vaccines	The portfolio that was consists of NeisVac-C and FSME-IMMUN/TicoVac.	Jul 30, 2014	$635M

Pfizer – Competitors

The top competitors of Pfizer are Merck, Novartis, BMS, Johnson & Johnson, GSK, Abbott, Cipla, Roche, Eli Lilly, and Bayer.

Pfizer – Challenges Faced

With exclusivity for Pfizer’s second-best-selling medication, Lyrica, expected to expire in June, the pharma expects a $2.6 billion sales hit from competitive pressures, almost $1 billion more than in 2018.
As of November 2020, Pfizer’s Covid-19 vaccine, made in partnership with the German firm BioNTech, was stored at subzero temperatures, and there were lots of distribution challenges in rolling it out in the weeks ahead.

Pfizer is “running at critical supply limitations,” Dr. Bourla, the CEO said, adding that he hopes the government deploys the Defense Production Act to solve the problem.

Meanwhile, the FDA contacted Pfizer about a different problem with its vaccine. According to some press accounts, several pharmacists giving the shots found that each vial contained more than the planned five doses. They wondered if they could eke out another dose, or even two, from the leftovers.

Pfizer – Future Plans

Pfizer has revealed plans to increase sales in Latin America, Eastern Europe, and Asia, which are all developing markets. The organization will use its global reach and product portfolio to provide health solutions to the rising and underserved population of middle-income patients in these areas.

The company identified four factors that will aid its expansion in the developing Asian pharmaceutical market, which is worth $47 billion. Expanding its current presence in high-growth markets, establishing leadership in oncology, tailoring portfolio offerings to local consumer needs, and leveraging global manufacturing and R&D in Asia are among these factors.

Pfizer expects to spend $5 billion in capital projects in the United States over the next five years, including expanding its manufacturing footprint in the country. In 2019, it announced an additional half-billion-dollar investment in Sanford, North Carolina, for the construction of a cutting-edge gene therapy manufacturing facility.

Pfizer – FAQs

What does Pfizer do?

Pfizer is a research-based multinational biopharmaceutical corporation that develops, manufactures, and distributes healthcare products. Medicines and vaccines are part of its global portfolio.

Who founded Pfizer?

Charles Pfizer and Charles Erhart, cousins who had immigrated to the United States from Ludwigsburg, Germany, founded Pfizer in 1849.

Which companies do Pfizer compete with?

The top competitors of Pfizer are Merck, Novartis, BMS, Johnson & Johnson, GSK, Abbott, Cipla, Roche, Eli Lilly, Bayer.

Does Pfizer produce Covid-19 vaccine?

Yes, Pfizer produces Covid-19 vaccine.

Does Pfizer export Covid-19 vaccine?

Yes, Pfizer exports Covid-19 vaccine.

May 10, 2021

Panacea Biotec Company Profile – India’s 2nd Largest Vaccine Maker

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Panacea Biotec.

Since the pandemic began, India has recorded more than 19 million cases, second only to the United States. Over 200,000 deaths have also been recorded. A total of 150 million vaccine shots were given out, covering 11.5 percent of India’s population of 1.3 billion people. Panacea Biotec is a pharmaceutical and vaccine company based in New Delhi, Mumbai, and Lalru in India.

Panacea Drugs Pvt. Ltd. was established in 1984 and became Panacea Biotec Ltd. in 1995. India’s second largest vaccine manufacturer, Panacea Biotec, offers a highly advanced prescription product range in essential therapeutic areas such as pain control, diabetes care, renal-disease management, anti-osteoporosis, anti-tubercular gastro-intestinal care drugs, and vaccines.

Know the entire Company Profile of Panacea Biotec in the post ahead! Also get a glance on Panacea Biotec vaccine news, its business model, how it started, Panacea Biotec products and more…

Panacea Biotec – Company Highlights

Company Name	Panacea Biotec
Headquarters	New Delhi, India
Industry	Pharmaceuticals, healthcare
Founded	1984
Key People	Soshil Kumar (Executive Chairman of the Board), Dr. Rajesh Jain (Managing Director), Sandeep Jain (Joint Managing Director)
Products	Pharmaceuticals, generic drugs, vaccine
Website	panaceabiotec.com

Panacea Biotec – Latest News
About Panacea Biotec and How it Works?
Panacea Biotec – Mission and Vision
Panacea Biotec – Founder and History
Panacea Biotec – Products
Panacea Biotec – Name, Logo, and Tagline
Panacea Biotec – Business Model
Panacea Biotec – Key Financial Metrics
Panacea Biotec – Funding and Investors
Panacea Biotec – Competitors
Panacea Biotec – Challenges Faced
Panacea Biotec – Future Plans
Panacea Biotech – FAQs

Panacea Biotec – Latest News

As of April 2021, the stock of Panacea Biotech has risen to levels not seen in more than a decade.

“The Russian Direct Investment Fund (RDIF), and Panacea Biotec announced cooperation to produce 100 million doses per year of Sputnik V, the world’s first registered vaccine against coronavirus,” the company said in a press release on April 4.

Production of Sputnik V at Panacea Biotec sites would aid in RDIF’s foreign partners’ global supply of Sputnik V. Sputnik V has been registered in fifty-nine countries with a total population of more than 1.5 billion people around the globe. Data published in the Lancet, one of the world’s oldest and most respected medical journals, shows that Sputnik V has around ninety-two percent efficacy score.

“The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots,” it said.

About Panacea Biotec and How it Works?

On February 2, 1984, Panacea Drug was incorporated as Panacea Biotec Limited, India’s leading science-based health management company with established research manufacturing and marketing expertise.

India’s second largest vaccine manufacturer, Panacea Biotec, offers a highly advanced prescription product range in essential therapeutic areas such as pain control, diabetes care, renal-disease management, anti-osteoporosis, anti-tubercular gastro-intestinal care drugs, and vaccines.

The business has collaborated with established national and international research businesses and organizations. PBL has four research and development centers and ultra-modern state-of-the-art production facilities in Himachal Pradesh, Punjab, and Delhi for manufacturing vaccines and pharmaceutical formulations that meet US-FDA, UK-MHRA SAMCC, and WHO-cGMP requirements.

In addition, the company owns 24 product patents that are valid in over 60 countries around the world. Radicura Pharma, a vaccine manufacturing plant opened in 1988, and Panacea Drug, a pharmaceutical formulations plant opened in 1989, in New Delhi.

Panacea Biotec – Mission and Vision

Panacea Biotec’ s mission is derived by its core values:

Innovation
Pioneer
Integrity
Humane

Panacea Biotec was established in 1984 as Panacea Drugs Private Limited, with the aim of making innovative products affordable and available to the general public.

Panacea Biotec – Founder and History

Panacea Biotec Ltd was established in 1993 as a result of a merger between Panacea Drugs (P) Ltd and Radicura Pharma. Panacea Biotec built a state-of-the-art Drug Delivery R&D center in Lalru in 1995, the same year it launched its initial public offering. The company received its first product patent in many countries in 1997.

In 2001, PBL’s Research & Development formed a partnership with a European MNC, and in 2002, an in-licensing agreement with the Biotechnology Consortium of India was signed for the development and commercialization of the anthrax vaccine. The company also opened a Recombinant Vaccine Manufacturing Plant in the same year, 2002.

In 2004, PBL signed an in-licensing agreement for the marketing of Japanese Encephalitis Candidate Vaccines with the National Institute of Immunology in New Delhi, and a collaboration with Cambridge Bio-stability UK for Thermo Stable Vaccines.

Key People/Executive Directors of Panacea Biotec –

Soshil Kumar (Executive Chairman of the Board)
Dr. Rajesh Jain (Managing Director)
Sandeep Jain (Joint Managing Director)
Mr. Ankesh Jain, Director – Sales & Marketing

Panacea Biotec – Products

Panacea Biotec product range includes highly advanced pharmaceutical drugs in specialty clinical fields like Pain Management, Diabetes & Cardiovascular Management, Oncology, Renal Disease Management, Osteoporosis Management, Anti-tubercular, Gastro-intestinal Care Products, and Vaccines.

Panacea Biotec’s current business is focused on its leadership positions in India, which include Transplant, Nephrology, Diabetes, and Pain, as well as some unique products based on proprietary Drug Delivery Systems. Its first Nanotechnology-based medicine, PacliAll (Paclitaxel in protein-bound particles), was introduced in 2011 and was the world’s first generic for Abraxane, produced by Celgene USA.

Panacea Biotec – Name, Logo, and Tagline

Panacea Biotec Private Limited was established in 1993 as a result of a merger between Panacea Drugs and Radicura Pharma.

Panacea Biotec’ s tagline is “Innovation in support of life,” which implies the company is India’s leading science-based health management company with established research manufacturing and marketing expertise.

Company Logo of Panacea Biotec

Panacea Biotec – Business Model

Panacea Biotec is a pharmaceutical and vaccine company. Panacea Biotec’s product range includes highly advanced pharmaceutical drugs in specialty clinical fields

Oncotrust, Critical Care, Diacar, Procare, and Growcare are the five strategic business units (SBUs) that Panacea Biotec has created to sell and market pharmaceutical formulations.

Panacea Biotec has entered the Contract Research & Manufacturing Services (CRAMS) market with the aim of expanding its knowledge and experience in on-time and high-quality delivery to clients.

The Company has built a strong portfolio in the fast-growing, multi-million dollar CRAMS market, based on its strong capabilities and state-of-the-art facilities, and powered by the enthusiasm of its experienced and skilled people. From sourcing to production, packaging to growth, the Company’s CRAMS portfolio covers the entire spectrum of processes and services.

Panacea Biotec – Key Financial Metrics

The table below highlights some of the key financial metrics of Panacea Biotec extracted from the company’s annual reports.

Financial Metric	2019-20	2018-19
Total Income	5335.83	4522.83
PAT	(1530.7)	265.7
PAT Margin (%)	(31.70)	6.04
Equity Share Capital	61.25	61.25
Net Fixed Assets	5667.47	8232.42

Panacea Biotec – Funding and Investors

Panacea Biotec is a publicly traded company listed in stock exchanges. It has also received investments from India Resurgent Fund and more .

Date	Round	Amount	Lead Investors
Dec 21, 2019	Grant	$24.3M	–
Apr 8, 2019	Venture Round	$144M	India Resurgent Fund

Panacea Biotec – Competitors

Glenmark, Torrent Pharmaceuticals Limited., Ranbaxy, Cipla, Dr. Reddy’s, Lupin, Aurobindo, Sun Pharma, Zydus Cadila, Cadila Pharmaceuticals are the top ten competitors in Panacea Biotec’s competitive set.

Panacea Biotec – Challenges Faced

Panacea Biotec Ltd.’s stock plummeted after the US Food and Drug Administration sent a warning letter to its Baddi, Himachal Pradesh, unit, prohibiting new approvals.

Following an inspection on February 10, 2020, the US Food and Drug Administration released a warning letter outlining major violations of existing good manufacturing practice legislation for finished pharmaceuticals.

“Until you correct all violations completely and we confirm your compliance with CGMP (current good manufacturing practice), FDA may withhold approval of any new drug applications or supplements listing your firm as a drug manufacturer,” it said in the statement.

The company failed to develop laboratory controls, such as scientifically sound and acceptable requirements, guidelines, sampling plans, and test procedures, to ensure that materials, drug product containers, closures, in-process content, labelling, and drug products meet appropriate identification, power, consistency, and purity standards.

Panacea Biotec – Future Plans

To guide long-term development, Panacea Biotec plans to scale up its vaccine and pharmaceutical verticals. According to a company spokesperson, Panacea Biotec’s long-term growth ambitions include scaling up its current product range, developing new drugs, and expanding into new markets.

The company transferred its pharmaceutical formulations business, as well as related research and development and natural products extraction activities, to its wholly-owned subsidiary Panacea Biotec Pharma Limited during the year under review.

In June 2020, the company announced the formation of a joint venture company in Ireland with Refana Inc of the United States to produce a COVID-19 vaccine. Panacea Biotec will be in charge of product production and industrial manufacturing, while the JV agency will be in charge of clinical development and regulatory submissions all over the world, according to the agreement. In their respective territories, Panacea and Refana will sell and distribute the vaccine.

Panacea Biotech – FAQs

What does Panacea Biotech do?

Panacea Biotec is an Indian pharmaceutical and vaccine company with headquarters in New Delhi, Mumbai, and Lalru, in India.

What is Panacea Biotec Vaccine News?

Panacea Biotec is India’s second largest vaccine manufacturer. The Russian Direct Investment Fund (RDIF) and Panacea Biotec announced cooperation to produce 100 million doses per year of Sputnik V, the world’s first registered vaccine against coronavirus (April 2021)

How Panacea Biotec Started?

Panacea Biotec Ltd was established in 1993 as a result of a merger between Panacea Drugs (P) Ltd and Radicura Pharma.

What are Panacea Biotec Products?

Panacea Biotec product range includes highly advanced pharmaceutical drugs in specialty clinical fields like Pain Management, Diabetes & Cardiovascular Management, Oncology, Vaccines among others. Its first Nanotechnology-based medicine, PacliAll was the world’s first generic for Abraxane.

Who are the competitors of Panacea Biotec?

Glenmark, Torrent Pharmaceuticals Limited., Ranbaxy, Cipla, Dr. Reddy’s, Lupin, Aurobindo, Sun Pharma, Zydus Cadila, Cadila Pharmaceuticals are the top ten competitors of Panacea Biotec

May 7, 2021

Serum Institute of India – Leading Biotechnology Firm

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Serum Institute of India.

India has reported more than 19 million cases since the pandemic started, second only to the United States. There have also been over 200,000 deaths recorded. A total of 150 million vaccine shots have been administered, covering 11.5 percent of India’s 1.3 billion population. Serum Institute of India is India’s leading biotechnology firm, producing highly advanced life-saving biologicals such as vaccines, antisera, and other medical specialties using cutting-edge genetic and cell-based technologies. Dr. Cyrus Poonawalla established the Serum Institute of India in 1966 with the aim of producing life-saving immuno-biologicals

Serum Institute of India Pvt. Ltd. is now the world’s largest vaccine manufacturer, with more than 1.5 billion doses manufactured and distributed worldwide.

Know the complete Success story of Serum Institute and get a glance on on how Serum Institute started, its revenue, business model, its role in Covid-19 vaccine development, competitors & more…

Serum Institute – Company Highlights

Startup Name	Serum Institute of India
Headquarters	Hadapsar, Pune, India
Industry	Biotechnology, Pharmaceuticals
Founder	Cyrus S. Poonawalla
Founded	1966
Current CEO	Adar Poonawalla
Subsidiaries	Vakzine Projekt Management GmbH, Bilthoven Biologicals BV
Areas Served	Worldwide
Website	www.seruminstitute.com

Serum Institute – Recent News
About Serum Institute and How It Works?
Serum Institute – Name, Logo and Tagline
Serum Institute – Founder and History
Serum Institute – Mission and Vision
Serum Institute – Covid 19 Vaccine Development
Serum Institute – Revenue and Growth
Serum Institute – Investments
Serum Institute – Acquisitions
Serum Institute – Competitors
Serum Institute – Challenges Faced
Serum Institute – Future Plans
Serum Institute – FAQs

Serum Institute of India – Recent News

May 2021 – CEO Adar Poonawalla, who has been in the United Kingdom on an extended stay to avoid alleged threats in India over rising demand for COVID-19 vaccines, has announced that he will return in a few days.

Had an excellent meeting with all our partners & stakeholders in the U.K. Meanwhile, pleased to state that COVISHIELD’s production is in full swing in Pune. I look forward to reviewing operations upon my return in a few days.

— Adar Poonawalla (@adarpoonawalla) May 1, 2021

About Serum Institute of India and How It Works?

Serum Institute of India Pvt. Ltd. is now the world’s largest vaccine manufacturer, with more than 1.5 billion doses manufactured and distributed worldwide, including Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Rubella vaccines.

Serum Institute vaccines are administered to approximately 65 percent of the world’s children. The Serum Institute’s vaccines are approved by the World Health Organization in Geneva and are used in over 170 countries around the world as part of their national immunization programmes, saving millions of lives.

The Serum Institute of India uses cutting-edge technology to scan its goods for minute particles that are undetectable by the naked eye. The inspection is completely automated, with high resolution CCD cameras and an electronic monitored panel, reducing the margins of human error.

Tetanus antitoxin, snake antivenom, DPT vaccine, and MMR vaccine were among the first drugs manufactured in large quantities by the Serum Institute of India. Vaccines against bacterial and viral infections, combined vaccines, influenza vaccine, and meningococcal vaccine were added to the company’s product line.

Serum Institute of India – Mission and Vision

Serum Institute’s mission is to develop high-quality vaccines and make them affordable to a wide range of countries, allowing them to increase their Health Index. The Serum Institute was founded to ensure that vaccines are no longer a privilege for Indian children.

Serum Institute began supplying high-quality, but affordable vaccines to many countries around the world after achieving this aim. International agencies such as the WHO, PATH, NIH, NVI/RIVM, and CBER/USFDA have collaborated with Serum Institute to produce vaccines against Meningococcal A, H1N1 Influenza, Rotavirus, and other diseases.

Serum Institute of India – Name, Logo and Tagline

Serum Institute of India’s tagline says, “Serum – Protection from birth onwards”. The company is the world’s largest vaccine manufacturer and produces vaccines(including Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Rubella vaccines) that protect people from birth onwards.

Serum Institute of India – Founder and History

Dr. Cyrus Poonawalla established the Serum Institute of India in 1966 with the aim of producing life-saving immuno-biologicals that were in short supply in India and had to be imported at a high cost.

Founder of SII - Dr. Cyrus Poonawalla — Founder of SII – Dr. Cyrus Poonawalla

Following that, many life-saving biologicals were produced at reasonable prices and in large quantities, resulting in the country being self-sufficient in Tetanus Anti-toxin and Anti-snake Venom serum, then DTP (Diphtheria, Tetanus, and Pertussis) vaccines, and finally MMR (Measles, Mumps, and Rubella) vaccines.

Vaccines against bacterial and viral infections, combined vaccines, influenza vaccine, and meningococcal vaccine were added to the company’s product line. Apart from vaccines, the company also produces antisera, blood plasma, and hormones. The Serum Institute of India’s vaccines has been used in international vaccination programs run by the World Health Organization (WHO), UNICEF, and the Pan American Health Organization as of 2014. (PAHO). The Poonawalla Group now runs the Serum Institute of India, which is involved in research, production, and manufacturing.

In 2009, the company started working on a swine flu vaccine that would be administered intranasally. Bilthoven Biologicals, a pharmaceutical firm in the Netherlands, was the company’s first foreign purchase in 2012.

The Serum Institute of India developed Rabies Human Monoclonal Antibody (RMAb), also known as Rabishield, with help from Mass Biologics of the University of Massachusetts Medical School in the United States.

CEO of SII - Adar Poonawalla — CEO of SII – Adar Poonawalla

By 2020, the company will have developed 1.5 billion vaccine doses each year, making it the world’s largest vaccine manufacturer by amount of doses produced. Tuberculosis vaccine Tubervac (BCG), poliomyelitis vaccine Poliovac, and other childhood vaccines are among the products created.

Serum Institute of India – Covid 19 Vaccine Development

AstraZeneca, a British-Swedish multinational pharmaceutical firm, has teamed up with Oxford University to grow AZD1222. According to reports, Serum Institute will provide India and other low- and middle-income countries with 100 million (10 crores) vaccine doses.

By the end of 2021, the target had been raised to one billion doses. It’s expected to cost about $3 per dose or around 225 dollars. Trials were suspended by DCGI in September 2020 after a volunteer in Oxford became ill after being vaccinated, but were quickly resumed after British regulators agreed. The Serum Institute of India applied for emergency approval for the vaccine produced with AstraZeneca in December 2020, and it was granted a month later. A deal was reached in March 2021 to supply certain doses to the United Kingdom.

The Serum Institute of India has also agreed to produce Novavax’s NVX-CoV2373 vaccine for India and other low- and middle-income countries. Codagenix’s nasal COVID-19 vaccine CDX-005 will also be manufactured by the company (tradename COVI-VAC)

Serum Institute of India – Revenue and Growth

SII’s net sales in 2018-19 were Rs 5,238 crore, with an after-tax profit of Rs 2,252 crore. The compounded annual growth rate (CAGR) for revenue was 8.1 percent over five years (2014-2019), while the CAGR for profit after tax was 5.3 percent. In 2019, SII’s export earnings accounted for more than two-thirds of its net sales. At the end of 2019, it had total assets of Rs 16,703 crore.

The pharma giant AstraZeneca and the University of Oxford collaborated on the Covid-19 vaccine. Covishield has a 62 percent efficacy rate. The SII has already generated a stock of approximately 5 crore doses. By February, it claims to be able to increase production to 10 crore doses per month.

Serum Institute of India – Investments

Date	Organization Name	Round	Amount
Jul 23, 2019	X-Vax Technology	Series A	$56M
Oct 5, 2017	Visterra	Series C	$23.6M

Serum Institute of India – Acquisitions

Acquiree Name	About Acquire	Date	Amount
Nanotherapeutics	Privately held specialty biopharmaceutical company with product development, cGMP manufacturing capabilities	Apr 25, 2017	€72M

Serum Institute of India – Competitors

Biocon, Panacea Biotec, Bharat Serums, Wockhardt, Biological E, Bharat Biotech, Syngene International, Indian Immunologicals, Premas Biotech, Reliance Life Sciences, and Zydus Cadila are among the other leading competitors in Serum Institute’s competitive set.

Cadila Healthcare, India’s fifth largest pharmaceutical firm, is working on an indigenous vaccine for the novel coronavirus in addition to producing Covid treatment drugs like remdesivir. Phase-III trials on 26,000 Indian patients have been approved by the government. The vaccine’s price has yet to be determined by Cadila.

Serum Institute of India – Challenges Faced

According to Poonawalla, the real challenge in 2020 will be determining if the Covid vaccine will actually function and be effective in humans. It was also difficult to demonstrate its effectiveness and plan a trial in a country where outbreaks are likely to occur, most likely China.

According to the CEO, “Our journey now is looking and has lot of challenges because we are trying to enter the Europe and US markets. We are trying to sensitize the Indian government to take more vaccines and plan and help them in their programmes to fight these life threatening diseases. We have got other challenges from China and other countries where we are offering a red carpet treatment for them to come here, but when we want to go to China, we have got a lot of barriers that we are facing like parting with our technology, we have got to do joint ventures things which are impossible.”

Serum Institute of India – Future Plans

As it struggles to fulfil supply obligations, the Serum Institute of India, which manufactures the AstraZeneca Covid-19 vaccine, is considering starting vaccine manufacturing in other countries.

“There’s going to be an announcement in the next few days,” Adar was quoted.

Poonawalla said the Serum Institute would be able to increase its monthly production to 100 million doses by July, a month later than the previous goal of end-May. Vaccines against Covid-19 have run out in some Indian states.

Within six months, he planned to increase the Serum Institute’s capability from 2.5 billion to 3 billion doses per year. He flew to London until Britain imposed an eight-day travel ban on Indians.

Serum Institute of India – FAQs

What does SII do?

Serum Institute of India is India’s leading biotechnology firm, producing highly advanced life-saving biologicals such as vaccines, antisera, and other medical specialties using cutting-edge genetic and cell-based technologies.

Who founded SII?

Dr. Cyrus Poonawalla established the Serum Institute of India in 1966 with the aim of producing life-saving immuno-biologicals that were in short supply in India and had to be imported at a high cost.

Does SII produce Covid Vaccine?

Yes, SII produces Covid vaccine.

Does SII export Covid vaccine?

Yes, SII exports Covid vaccine out of India.

May 6, 2021

List of Companies developing Covid 19 vaccine around the World

The vaccination drive for Covid 19 has been started across the globe. Vaccines have been developed and manufactured by a lot of companies around the world. Below are the top companies which are involved in the development and manufacturing of Covid vaccines.

Pfizer
Astra Zeneca
Serum Institute of India
Bharath Biotech
Moderna
BioNTech
Novavax
Sinovac
CanSino Biologics
Johnson & Johnson
Inovio
R-Pharm
BIOCAD
Pharmasyntez
FAQ

Pfizer

Pfizer is an American based pharmaceutical company. It was founded in the year 1984 and has its headquarters in New York. Pfizer is one of the world’s largest pharmaceutical company. The company develops and manufactures vaccines and medicines for a wide range of medical disciplines.

Pfizer is in the process of development and manufacturing of mRNA vaccine for Covid 19.

Astra Zeneca

Astra Zeneca is a British-Swedish multinational biotechnology and pharmaceutical company. The company has its headquarters in Cambridge, England and was founded in the year 1999. Astra Zeneca has a portfolio of products for major diseases in areas such as oncology, cardiovascular, infection, respiratory, etc.

Astra Zeneca is well known for its involvement in developing the Oxford-Astra Zeneca Covid 19 vaccines.

Serum Institute of India

Serum Institute of India is an Indian Pharmaceuticals and Biotechnology company. It is the largest manufacturer of Vaccines around the globe. The company was founded in 1966 by Cyrus Poonawalla and is based in Pune, India. Adar Poonawalla is the Chairman, President, and CEO of the company.

Serum Institute of India has tied up with Astra Zeneca which is a pharmaceutical company. The company has released a vaccine called Covishield.

Bharath Biotech

Bharath Biotech International Limited is an Indian company which deals with biotechnology. The company has its headquarters in Hyderabad, India. The company is involved in drug development, manufacture of vaccines, drug discovery, bio-therapeutics, healthcare products, and pharmaceuticals.

It has partnered with the state-run Indian Council of Medical research in developing a vaccine against Covid-19 called as COVAXIN.

Moderna

Moderna is a an American-based biotechnology and pharmaceutical company. The company has its headquarters in Cambridge. The company focuses on discovery of drugs, development of drugs and vaccine technologies.

Moderna is in the process of developing mRNA vaccine for Covid 19.

BioNTech

BioNTech is the short form for Biopharmaceutical New Technologies. It is a German based biotechnology company which has its headquarters in Mainz Germany. The company was founded in the year 2008.

BioNTech is also in the process of developing mRNA vaccine for Covid 19.

Novavax

Novavax is an American based Pharmaceutical company which is involved in the manufacturing of vaccines. The company was founded in the year 1987 and is located in Gaithersburg United States.

Novavax is in the process of development and manufacturing NVX-CoV2373 which is a vaccine for Covid 19.

Sinovac

Sinovac Biotech Ltd is a Chinese based biotechnology company. The company was founded in the year 1999 which is located in Beijing, China. The company focuses in the research and development, commercialization and manufacturing of vaccines which will protect against human infectious diseases.

Sinovac Biotech Ltd is in the process of development and manufacturing of CoronaVac which is a vaccine for Covid 19.

CanSino Biologics

CanSino Biologics is a Chinese vaccine company. The company was founded in the year 2009 and is headquartered in Tianjin, China. The company is in the process of development and manufacturing of Ad5-nCOV which is a vaccine for Covid 19.

**Rate of COVID-19 vaccination worldwide as of April 10, 2021**

Johnson & Johnson

Johnson & Johnson is an American multinational corporation. The company was founded in the year 1886 and has its headquarters in New Jersey, New York. It focuses on developing medical devices, consumer packaged goods and pharmaceuticals.

Johnson & Johnson is in the process of developing Ad26.COV2.S which is a type of vaccine for Covid 19.

Inovio

Inovio Pharmaceuticals is an American based biotechnology company. It was found in the year 1983 and has its headquarters in Pennsylvania. It focuses on the development, discovery and commercialization of synthetic DNA products. The products are used for treating Cancer and infectious diseases.

Inovio Pharmaceuticals is in the process of developing INO-4800 which is a DNA based plasmid Covid 19 vaccine.

R-Pharm

R-Pharm is an international pharmaceutical company. It has its headquarters in Russia. The company was founded in the year 2001 by Alexey Repik. The company concentrates on areas which include research, development, production and marketing of drugs which is primarily on inpatient and medical care.

Their main focus is on activities such as production of finished dosage forms, research and development of drugs and technologies, introduction to Russian market of pharmaceuticals, etc.

In December 2020, the company had got into a memorandum of understanding (MOU) with Astra Zeneca in the manufacturing of Oxford Astra Zeneca Covid-19 Vaccine.

BIOCAD

BIOCAD is a Russian based pharmaceutical company. The company has its headquarters in Saint Petersburg, Russia. The company has offices in Belarus, India, China, Brazil and even United States. It is said that 40% of the company’s employees are scientists.

The company focuses on discovering, developing and manufacturing vertically integrated drugs. The company has around 50 products in its portfolio. BIOCAD is currently developing a mRNA vaccine for Covid-19.

Pharmasyntez

Pharmasyntez is a Russian based Pharmaceutical company. The company was founded in the year 1997 in Irkutsk. The first factory of the company was opened in the year 1999.

The company has more than 50 products in its portfolio. The company also supplies medicines to the largest pharmaceutical distributors in Russia. It is one of the top 3 fastest growing pharmaceutical companies in Russia.

Pharmasyntez is expected to start the production of Covid-19 vaccine Sputnik V.

FAQ

Is India exporting Covid vaccine?

Indian government has decided not to ban the commercial export of Covid-19 vaccines by the two manufacturers based in India, for now.

Who issued the official name of COVID-19?

The official names COVID-19 and SARS-CoV-2 were issued by the WHO on 11 February 2020.

Is the US using AstraZeneca vaccine?

AstraZeneca’s Covid-19 vaccine has not yet been rolled out in the U.S. as the Food and Drug Administration (FDA) has only authorized the use of vaccines developed by Pfizer, Moderna and Johnson & Johnson.

Conclusion

These are the top companies in the world that is involved in the manufacturing and development of Covid 19 vaccines.

April 16, 2021

Top 3 Generic Medicine Startups That Are Reshaping the Pharmaceutical Industry in India

Medicine is considered one of the most essential needs for all of us. The Indian Pharmaceutical space is witnessing a storm of new start-ups, not only for cash flow opportunities the sector offers but for making affordable medicines. Lack of access to good quality and affordable medicines is a major challenge in Indian healthcare.

Medicine is concerned with maintaining and restoring human health, and the role of the pharmacist is vital for the benefit of patients. Not all medicines are available at low prices and thus not everyone can afford them. So for those customers who cannot afford expensive brand medicines, there is a generic medicine which is at a fairly low price. Here we are going to talk about the Top 3 Generic Medicine Startups that are Reshaping the Pharmaceutical Industry in India.

What Are Generic Medicines?
Generic Medicines Are Safe?
Top 3 Generic Medicine Startups in India
StayHappi
Zeno Health (Generico)
Generic Aadhar

What Are Generic Medicines?

Generic drugs are identical to brand-name drugs that have the same dosage, intended use, effects, side effects, route of administration, risks, safety, and strength as the original drug. Generic drugs are only cheaper because the manufacturers have not had the expense of developing and marketing a new drug.

Generic Medicines Are Safe?

Generic medicines are as safe as branded medicines. The FDA requires that generic drugs work as fast and effectively as brand-name drugs. The reason generic drugs are cheaper is that companies don’t have to spend on research and development of generic drugs if they have patents for brand-name drugs.

Top 3 Generic Medicine Startups in India

StayHappi

Startup Name	StayHappi
Headquarter	Delhi, India
Industry	Pharmaceutical
Founder	Arushi Jain
Founded	October 2017
Parent Organization	SarvaGunAushdhi Private Limited
Products	Allopathic, Ayurvedic, Herbal medicines, Neutraceuticals, OTC, Consumables, Cosmetics, Surgical items and Medical Devices.

StayHappi was founded by Arushi Jain in October 2017. StayHappi Pharmacy offers these legitimate medicines at reasonable prices and empowers them to make the right choice. They offer high-quality generic medicines at 30- 90% lower MRP as compared to branded medicines and are leading the way in making healthcare more affordable.

StayHappi Pharmacy provides high-quality generic medicine so that people can get the best allopathic medicines at the most affordable prices. There is a growing demand for nutraceuticals and StayHappy provides these products as well. StayHappy Store also offers Ayurvedic Medicines, to cater to the health care basket and cater to people who have a penchant for Ayurvedic and herbal medicines. StayHappy also provides medical consumables and cosmetics at its stores.

Zeno Health (Generico)

Startup Name	Zeno Health (formerly Generico)
Headquarter	Mumbai, Maharashtra
Industry	Pharmaceutical
Founder	Siddharth Gadia
Founded	May 2017
Products	Cardiovascular, Gastrointestinal, CNS, Urology, Disorders of Aging

Generico was founded by Siddharth Gadia in 2017. Fastest-growing speciality pharmacy retail chain of generic drugs. Started by IIT Bombay alumni, Generico aims to make healthcare affordable for millions of Indians. It offers the largest portfolio of generic drugs from reputed pharma companies under one roof and offers up to 80% lower prices.

Zeno Health is India’s fastest-growing pharmacy retail company, with a presence in 100+ locations and the biggest private generic player in India. Zeno Health aims to satisfy consumer needs of trust in the quality of medicines, easy availability and best price, in accordance with their mission statement– Think Medicines, Think ZenoHealth.

Generic Aadhar

Startup Name	Generic Aadhar
Headquarter	Maharashtra, India
Industry	Pharmaceutical
Founder	Arjun Deshpande
Founded	2019
Products	Medical Supplies

Generic Aadhar was founded by Arjun Deshpande in 2018 in Thane. Generic Aadhaar provides generic quality medicines from reputed pharma companies at up to 80% fewer prices. It offers a wide portfolio of branded, generic, homoeopathy and Ayurveda medicines from government-approved manufacturing facilities.

pharmaceutical startup — **Generic Aadhar**

Generic Aadhaar aims to partner with 1000 pharmacies on a franchise-based model in the coming months and expand its reach to markets such as Tamil Nadu, Andhra Pradesh, New Delhi, Goa, Rajasthan, and Gujarat. Ratan Tata has invested an undisclosed amount in this pharmaceutical startup Generic Aadhar.

Conclusion

Generic medicine startups are doing a great job by providing generic medicines at affordable prices to customers who cannot afford branded medicines. As India is the largest provider of generic drugs globally, the Indian pharmaceutical sector supplies more than 50 per cent of the global demand for various vaccines, 40 per cent of generic demand in the US, and 25 per cent of all drugs in the UK. It is also expected to grow to US$ 100 billion by 2025.

FAQ

How to start a generic medicine business?

Start with the premises of your office, a unique and meaningful brand name, and finances. Then get your business registered. The main steps of registration are Digital Signature Certificate, Director Identification Number, getting user registration, and filling out the e- form. The next steps include getting the GST number, trademark registration, and FSSAI registration.

What is an example of a generic medicine?

The majority of drugs, particularly life-saving are manufactured and sold as generic drugs. One example of a well-known generic drug is metformin, which is used to lower blood sugar levels in diabetes.

What are generic medicines?

According to FDA generic drug is a medication created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.

Is the generic medicine business profitable?

Yes, according to a recent study margin on generic medicines can be 100%. As per recent reports, the Indian pharmaceutical industry is largely dominated by ‘branded generics’ that are cheaper, more effective, and safer. India is the second-largest producer of generic drugs, therefore, the generic market is anticipated to offer so much to the Indian economy.

February 26, 2021

McKesson Unveils Insight Into Hospital Pharmacy Trends

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by the organization it is based on.

McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools. The company had revenues of $231.1 billion in 2020.

McKesson is based in Irving, Texas and distributes health care systems, medical supplies and pharmaceutical products. Additionally, McKesson provides extensive network infrastructure for the health care industry; also, it was an early adopter of technologies like bar-code scanning for distribution, pharmacy robotics, and RFID tags.

McKesson – Company Highlights

Startup Name	McKesson Corporation
Former Names	Olcott & McKesson(1833–1853), McKesson & Robbins(1853–1999), McKessonHBOC(1999–2001)
Headquarters	Irving, Texas, U.S.
Industry	Healthcare
Founded	1833
Founder	McKesson, Charles Olcott
CEO	Brian S. Tyler
Areas Served	Worldwide
Website	www.McKesson.com

McKesson – About and How it Works?
McKesson – Logo and its Meaning
McKesson – Founder and History
McKesson – Mission
McKesson – Business Model
McKesson – Revenue and Growth
McKesson – Investments
McKesson – Acquisitions
McKesson – Competitors
McKesson – Challenges Faced
McKesson – Future Plans

McKesson – About and How it Works?

McKesson Corporation is a healthcare supply chain management solution, retail pharmacy, community oncology and speciality care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare.

It operates through three segments: United States Pharmaceutical and Speciality Solutions, European Pharmaceutical Solutions and Medical-Surgical Solutions. The United States Pharmaceutical and Speciality Solutions segment distributes pharmaceutical and other healthcare related products and provides pharmaceutical solutions to life sciences companies. European Pharmaceutical Solutions segment provides distribution and services to wholesale, institutional and retail customers. Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers.

McKesson – Logo and its Meaning

The McKesson logo is a great example of how a simple strict word mark can look modern and stylish.

Logo of McKesson

The brand’s logo is composed of its word mark and the slogan beneath. The key role in the logo design takes the colour palette. Its main colour is common for the pharmaceutical industry design blue. But it has a small and bright accent, which changes everything – an orange line under the letter “C”.

This colour accent makes the logo look fresher and contemporary, even though the typefaces used in the word mark and slogan are both very classic.

McKesson – Founder and History

In 1833 Charles Olcott and his partner John McKesson founded Olcott & McKesson, a wholesaler and importer of botanical drugs. Twenty years later, with the death of Olcott and the addition of Daniel Robbins, the firm was renamed McKesson & Robbins. Over the next 100 years the company grew significantly by persuading other distributors of wholesale drugs to become its subsidiaries.

In 1967 the firm faced a hostile takeover by Foremost Dairies, being renamed Foremost-McKesson. The parent had no corporate strategy and began acquiring diverse businesses, from sporting goods to candy. In 1976, new executives worked to streamline its operations by selling low-profit units. They also reorganized it into four groups: drugs/healthcare, wine/spirits, foods, and chemicals.

The new leaders also aimed to redefine the firm’s “middleman” distributor role by making it more indispensable. They did so by offering data processing procedures that were essential for both customers and suppliers, enabling the company to act as part of their marketing teams. The value-added partnership was prized by small businesses that had difficulty competing with national chains.

The strategy made it a top wholesaler and led to annual profit increases of 20% on average. In 1979, it divested over one-third of its holdings to focus on retail and healthcare products. It also began acquiring much healthcare product distribution firms, including technology-related outfits, and shortened its name to McKesson in 1984. By 1990 it was the leader of the drug wholesaling industry.

McKesson – Mission

McKesson’s mission statement says, “To provide products, services and solutions of the highest quality and deliver more value to our customers that earns their respect and loyalty.”

McKesson – Business Model

McKesson is a distributor and provider of healthcare services and technology. The company operates two reportable business segments:

Distribution Solutions – Distributes generic and branded pharmaceutical drugs and other healthcare-related products, and provides practice management, clinical support, technology, and business solutions to community-based oncology and other speciality practices.
Technology Solutions – Provides enterprise-wide clinical, financial, patient care, strategic management, and supply chain technology solutions, as well as outsourcing, connectivity, and other services (including managed and remote hosting services) to healthcare organizations.

McKesson – Revenue and Growth

| Year | Amount | Change From Last Year |
| — | — | — | — |
| 2020 | $234.194B | +5.5% |
| 2019 | $214.319B | +2.86% |
| 2018 | $208.357B | +4.95% |

McKesson – Investments

McKesson has made 2 investments. Their most recent investment was on Mar 27, 2019, when Xealth raised $11M.

Date	Organization Name	Round	Amount
Mar 27, 2019	Xealth	Series A	$11M
Mar 29, 2017	SHYFT	Series B	$7.5M

McKesson – Acquisitions

McKesson has acquired 44 organizations. Their most recent acquisition was Echo on Jun 19, 2019.

Acquiree	Date	Amount	About Acquiree
Echo	Jun 19, 2019	–	Simplifying pharmacy, helping everyone get the medicine they need
Medical Specialties Distributors	Apr 25, 2018	–	Full service medical supply and biomedical equipment distributor
Well.ca	Dec 4, 2017	–	Well.ca is a Canadian online store for health, wellness, beauty and baby essentials
RxCrossroads	Nov 6, 2017	–	RxCrossroads Specialty Solutions is committed to connecting patients to therapy
CoverMyMeds	Jan 25, 2017	$1.1B	CoverMyMeds is a healthcare tech platform helping doctors and pharmacists complete PA and insurance coverage determination forms for drugs
HealthQx	Jul 12, 2016	–	HealthQx specializes in data analytics and decision support software to bring transparency to the healthcare industry
Vantage Oncology	Apr 4, 2016	$525M	Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology
Rexall	Mar 2, 2016	$2.1B	Rexall is a drugstore operator with a dynamic history of innovation and growth
Biologics	Feb 25, 2016	$1.2B	Biologics provides a patient-focused platform for managing the financial, emotional, and physical burdens of cancer treatment
UDG Healthcare	Sep 16, 2015	€408M	UDG Healthcare specializes in supply chain, packaging, medical, regulatory, and sales and marketing

McKesson – Competitors

McKesson top competitors include EMIS Group, Walgreens Boots Alliance, Owens & Minor, Henry Schein, AmerisourceBergen, Cardinal Health and Walgreens.

McKesson – Challenges Faced

Increasing complexity and growth in integrated delivery networks : The lines between care settings are blurring as hospitals integrate with medical practices, infusion centres and home care, to form sophisticated networks delivering comprehensive patient care. While the number of hospital mergers declined in 2018, mega mergers are the new standard. The need for business partners to help networks diminish complexity and streamline operations across the continuum of care has become increasingly important as leaders work diligently to do what is right for the patient.
Hospitals expanding speciality pharmacy footprint, swiftly : Speciality pharmacy has been a top trend for the past several years as utilization and drug spend have dramatically increased across healthcare. As hospital and health systems experienced nearly 20% growth in the speciality drug market in 2018, health systems continue to establish their own speciality pharmacies or expand their existing capabilities. Speed to therapy and ongoing patient support are still critical.
Out-of-pocket costs impacting patients and revenue : Speciality drugs have emerged as important treatment options for cancer and other complex diseases, but there can be significant access and affordability issues with speciality drugs. The cost of speciality medications and the increased adoption of high-deductible health plans (HDHP) have placed a higher financial burden on patients. As out-of-pocket costs increase – from higher costs or insurance denials – patients are more likely to abandon their treatment plans.
Finance and pharmacy leadership relying on data-informed decisions, not intuition : Pharmacy directors face increasing pressure from performance-based reimbursement and diminishing resources. To alleviate these pressures, pharmacists need to leverage data and analytics to reduce costs, help maintain a healthy bottom line and support quality patient care. However, not all health systems have the tools and resources to aggregate and sift through data in order to apply comprehensive, real-time analytics to deliver better care effectively while maintaining a healthy balance sheet.

McKesson – Future Plans

A new strategic planning solution for oncology practices is now available to customers through McKesson’s Business Advisory Services, a team of experts dedicated to helping speciality practices solve financial and operational challenges through consulting, analytics and technology.

“Tremendous change is happening in the healthcare industry, especially in oncology,” said Catherine Swick, VP of Speciality Provider Strategy at McKesson. “While practices cannot control the future, strategic planning can help them prepare for what may come, while identifying opportunities to remain strong and viable. As an advocate of community oncology, we are excited to offer our strategic planning solution to our oncology customers as it will enable them to grow and thrive in a way that’s meaningful and valuable to their practices.”

McKesson’s strategic planning process helps practices create a vision for the future, while equipping them with short-term tactical planning to drive momentum and results. The comprehensive planning process starts with an analysis of the practice’s data, so the McKesson team thoroughly understands its challenges and opportunities and the practice has baseline metrics to guide its discussion and decisions. This is followed by a facilitated retreat with physicians and key staff to align on top priorities and culminates in a detailed three-year action plan for each initiative selected by the practice, providing the structure to make daily decisions that follow the larger vision.

November 28, 2020

The Covid-19 Pandemic Proved To Be Lucrative For These Industries

The sudden outbreak of the Covid-19 pandemic has left no industries and sectors unscathed, worldwide. And many parts of the economy have taken a hit because of it.

While the pandemic has created global economic uncertainty, it has also proved to be lucrative for some industries and created new markets and opportunities. In fact, some of them are seeing more business than they ever have. The world has changed, for now, and so has the needs and wants of consumers.

How the Pandemic affected this industry in a good way.

These are the companies that are thriving even in these unprecedented times.

Online Training & Education Services

The coronavirus pandemic has led to the shutting down of schools, colleges, and other educational institutions. This has given rise to online home-based learning, using digital platforms. This has led to the acceleration in the integration of information technology in education, where online education has become an integral component of school education.

The increase in demand for the online training and education sector can lead to aggressive hiring. Even for those without any teaching qualifications, apart from tutoring, there are a plethora of jobs in this sector, like designing, communicating, software engineering, etc.

Home Goods

While people are forced to stay in homes due to the inescapable lockdown, they are now spending more time and money on redecorating and refurnishing their houses. They want to decorate every corner that seemed imperfect to them earlier but couldn’t buy time to take care of it.

Now that people spend every day, all day staring at their home, they are finally purchasing home decor products like potted plants, wall art, accent pillows among others.

Agricultural Technologies

The lockdown in various countries have severely diminished global production capacities and disrupted global supply chains. Food agencies over the world are planning to have the majority of the food produced locally by harnessing technology, increasing the amount of space dedicated to farming, and supporting local agriculture.

To scale up operations and meet the surge in demand for locally-produced crops, job opportunities in this sector are fast-growing. These jobs include horticulture technician, farm engineer (specializing in robotics and automation), an events executive for the marketing side of things, and the like.

Pharmacies

Health has become a priority more than ever. With deaths due to the coronavirus all around the corner, people are threatened and so they are prioritizing health issues above all. Pharmaceutical companies have added a surge of openings in the lockdown.

Home Fitness Equipment

Lockdown has enabled people to fulfill their long-forgotten or neglected fitness goals. While others want to maintain their form just like before the pandemic. But the closure of all gyms led them to boost the sales of home fitness equipment. As a result, many fitness enthusiasts and newbies are spending not just on yoga mats and small weights, they now want professional-quality home gym equipment, so their workouts don’t suffer during this quarantine.

Courier Pick-Up and Delivery Services

The delivery and pick-up industry is the most profitable in the coronavirus pandemic. Not only are people ordering food online, but they are also increasingly ordering essential groceries and other food items. Because of the fear of catching corona, people nowadays do not want to step out of their houses, especially in metropolitan cities. Hence, the delivery service is the need of the hour.

There are so many relevant employment opportunities included in this industry apart from being a delivery driver. From data analysts to UX designers to account management staff, there are plenty of well-paying choices for qualified jobseekers within the industry.

Delivery services of restaurant businesses

Tech Support

With physical call centers and operation centers closing down, companies are left with the need for agents to still take customer and technical support calls. Especially with the increase in remote work, more people than ever need support with setting up and pairing devices or troubleshooting errors.

SkinCare

Self-Care is trending nowadays. In response to the emotional stress of this time, many people are putting in a little extra effort with pampering themselves with skincare products. Many people also want to make sure they still look just as young and vibrant as they did entering this pandemic when they exit it. As a result, the skincare industry is on the rise.

Teleworking Software

Telecommunication has been on a steady incline for the last 5 years. As more states try to practice safety at home and maintain social distancing, companies have transitioned almost fully to remote work. In order to successfully enforce a work remote culture, employees need a broader reach through video conferences, online meetings, chat, and mobile collaboration services. This implies that telecommunication has been on a steep and sudden incline with teleworking software as the foundation for this new workplace model.

Augmented Reality Software

The retailers who are surviving this pandemic must adapt, and for many, that means turning to augmented reality (or virtual reality) software. Due to social distancing, everything has drifted online. Furniture companies are now creating apps to allow customers see how a chair might look in their living room. Realtors are offering clients apps that allow for 3D tours of homes. And of course, bored individuals at home are buying VR equipment for entertainment purposes.

Grocery Stores

The shopping markets have quickly transformed from the inevitable errand people used to have on their to-do lists to the only outing allowed throughout the quarantine. This leads to an increase in the business of grocery stores.

Supermarkets are also looking for support from stocking shelves all the way to managing supply chain logistics, handling public relations, and software development engineering.

In times of such great uncertainty, people’s routines and purchasing habits go out the window, which opens up the opportunity for businesses who can pivot operations and invest in new technologies to adapt to the changing climate. Now, more than ever, it’s important for companies to understand the environment we’re living in and adapt to it. These are the companies that will not only survive during the pandemic but also move ahead of their competition.

October 8, 2020

Tag: Pharmaceutical Companies